IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
27 February 2014 - 12:02AM
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian
drug delivery company focusing on oral drug delivery, today
announced that it has received a Notice of Allowance ("NOA") from
the United States Patent and Trademark Office for U.S. Patent
Application Serial No. 11/647,033 entitled "Multilayer tablet"
which covers the technology used in our hypertension product
currently under development. A second NOA has been received for
U.S. Patent Application Serial No. 11/782,838 entitled
"Controlled-release pharmaceutical tablets" which is related to the
drug delivery technology used in Forfivo XL®, IntelGenx' first
FDA-approved product currently commercialized in the U.S. These two
NOA's conclude the examination of each U.S. patent application and
will result in the issuance of two U.S. patents after
administrative processes are completed.
"These two additional NOA's in the U.S. represent yet another
important expansion of IntelGenx' patent estate as well as
demonstrating the innovative design of our drug delivery
technologies," said Rajiv Khosla, IntelGenx' President and Chief
Executive Officer. "Our goal is to protect the innovation and
commercial potential of the products developed at IntelGenx and
these NOA's further strengthen our proprietary position."
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly
disintegrating delivery systems. IntelGenx uses its unique multiple
layer delivery system to provide zero-order release of active drugs
in the gastrointestinal tract. IntelGenx has also developed novel
delivery technologies for the rapid delivery of pharmaceutically
active substances in the oral cavity based on its experience with
rapidly disintegrating films. IntelGenx' development pipeline
includes products for the treatment of indications such as severe
depression, hypertension, erectile dysfunction, migraine, insomnia,
CNS indications, idiopathic pulmonary fibrosis, oncology and pain,
as well as animal health products. More information is available
about the company at www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about
IntelGenx' operating results and business prospects that involve
substantial risks and uncertainties. Statements that are not purely
historical are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
Section 27A of the Securities Act of 1933, as amended. These
statements include, but are not limited to, statements about
IntelGenx' plans, objectives, expectations, strategies, intentions
or other characterizations of future events or circumstances and
are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "could," "would," and similar expressions. All forward
looking statements are expressly qualified in their entirety by
this cautionary statement. Because these forward-looking statements
are subject to a number of risks and uncertainties, IntelGenx'
actual results could differ materially from those expressed or
implied by these forward looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to, those discussed under the heading "Risk Factors" in
IntelGenx' annual report on Form 10-K for the fiscal year ended
December 31, 2012, filed with the United States Securities and
Exchange Commission and available at www.sec.gov, and also filed
with Canadian securities regulatory authorities and www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has neither approved
nor disapproved the contents of this press release.
CONTACT: Dr. Rajiv Khosla,
President and CEO
IntelGenx Corp.
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From Apr 2024 to May 2024
IntelGenx Technologies (QB) (USOTC:IGXT)
Historical Stock Chart
From May 2023 to May 2024